Skip to main content
. 2021 Jul 5;11:13834. doi: 10.1038/s41598-021-93392-5

Table 1.

Baseline and demographic characteristics.

Total (n = 30) Survivors (n = 23) Death/LT (n = 7) P-value
Male sex, n (%) 20 (67) 14 (61) 6 (86) 0.37
Age (years), median (range) 55.5 (38–74) 54 (38–71) 62 (47–74) 0.22
LiMAx one day before TIPS [µg/kg/h], median (range) 233 (77–538) 249 (77–538) 178 (90–205) 0.01
LiMAx one day after TIPS [µg/kg/h], median (range) 195 (65–345) 207 (65–345) 80 (75–214)  < 0.01
LiMAx drop one day after TIPS [µg/kg/h], median (range) -44.5 (-303–58) -44 (-303–58) -46 (-98–34) 0.86
HVPG pre TIPS [mmHg], median (range) 22 (14–34) 23 (15–34) 22 (14–29) 0.31
HVPG post TIPS [mmHg], median (range) 9 (5–12) 9 (5–12) 8 (5–12) 0.44
HVPG drop [mmHg], median (range) 14 (6–24) 14 (6–24) 13 (7–17) 0.54
TIPS diameter [mm], median (range) 8 (6–10) 8 (6–10) 6 (6–8) 0.14
MELD score, median (range) 12 (6–23) 10 (6–22) 16 (10–23) 0.02
Child Pugh score [points], median (range) 8 (5–11) 8 (5–11) 9 (7–11) 0.05
Child Pugh stage 0.40
 Class A, n (%) 3 (10) 3 (13) 0 (0)
 Class B, n (%) 20 (67) 16 (70) 4 (57)
 Class C, n (%) 7 (23) 4 (17) 3 (43)
Origin of cirrhosis (n, %) 0.60
Alcohol 22 (73) 17 (74) 5 (71)
NASH 5 (17) 4 (17) 1 (14)
HCV 1 (3) 0 (0) 1 (14)
PBC 1 (3) 1 (4) 0 (0)
AIH 1 (3) 1 (4) 0 (0)
Indication of TIPS placement (n, %) 0.30
Ascites 25 (83) 18 (78) 7 (100)
Variceal bleeding 5 (17) 5 (22) 0 (0)
Laboratory parameters (median, SD)
Platelets (per nL) 145 (124.1) 151 (134.9) 103 (49.9) 0.04
Creatinine (mg/dL) 1.1 (1.3) 1.1 (1.5) 1.9 (0.6) 0.11
Bilirubin (mg/dL) 1.0 (1.0) 1.0 (0.9) 1.8 (1.1) 0.29
AST (U/L) 41 (33.7) 42 (37.8) 36 (14.8) 0.35
ALT (U/L) 21 (20.4) 21 (23.4) 21 (6.7) 0.92
Albumin (g/dL) 3.2 (0.6) 3.2 (0.7) 3.0 (0.4) 0.59
INR 1.16 (0.2) 1.12 (0.2) 1.34 (0.2) 0.07

Bold values indicate statistically significant at P < 0.05.

AIH autoimmune hepatitis, ALT alanine aminotransferase, AST aspartate aminotransferase, HCV hepatitis C virus, HVPG hepatic venous pressure gradient, INR international normalized ratio, MELD model for end-stage liver disease, NASH non-alcoholic steatohepatitis, PBC primary biliary cholangitis, TIPS transjugular intrahepatic portosystemic shunt.